Bluejay Diagnostics annual return on equity
2021
2022
2023
2024
2025
Bluejay Diagnostics Return on Equity (ROE) Growth & History (BJDX)
Bluejay Diagnostics's return on equity was −117.02% for fiscal 2025.
View full Bluejay Diagnostics company overviewBluejay Diagnostics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −117.02% | +61.96 pp |
| 2024 | 2024-12-31 | −178.98% | −41.07 pp |
| 2023 | 2023-12-31 | −137.90% | −79.66 pp |
| 2022 | 2022-12-31 | −58.25% | −15.12 pp |
| 2021 | 2021-12-31 | −43.13% | — |
Bluejay Diagnostics quarterly return on equity
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −34.19% | +8.55 pp |
| Q1 2026 | 2026-03-31 | −37.79% | +1.07 pp |
| Q4 2025 | 2025-12-31 | −29.58% | −7.37 pp |
| Q3 2025 | 2025-09-30 | −35.57% | −16.82 pp |
| Q2 2025 | 2025-06-30 | −42.74% | −1.51 pp |
| Q1 2025 | 2025-03-31 | −38.86% | +35.51 pp |
| Q4 2024 | 2024-12-31 | −22.21% | +34.59 pp |
| Q3 2024 | 2024-09-30 | −18.75% | +20.90 pp |
| Q2 2024 | 2024-06-30 | −41.23% | −5.02 pp |
| Q1 2024 | 2024-03-31 | −74.37% | −49.83 pp |
| Q4 2023 | 2023-12-31 | −56.80% | −37.98 pp |
| Q3 2023 | 2023-09-30 | −39.66% | −20.23 pp |
| Q2 2023 | 2023-06-30 | −36.21% | −25.18 pp |
| Q1 2023 | 2023-03-31 | −24.53% | −14.17 pp |
| Q4 2022 | 2022-12-31 | −18.82% | +9.58 pp |
| Q3 2022 | 2022-09-30 | −19.43% | — |
| Q2 2022 | 2022-06-30 | −11.02% | — |
| Q1 2022 | 2022-03-31 | −10.36% | — |
| Q4 2021 | 2021-12-31 | −28.40% | — |
Bluejay Diagnostics return on equity trends
Between the periods ended 2021-12-31 and 2025-12-31, Bluejay Diagnostics's return on equity decreased from −43.13% to −117.02%, a change of −73.89 percentage points. The latest reported quarter, Q2 2026, shows −34.19%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Bluejay Diagnostics source filings ↗